ConductScience.org, home

Paper41328344

Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy.

Li Y and 14 others. Theranostics, 2026. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy. Papers, record 41328344. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41328344

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy.
PubMed
Journal
Theranostics
PubMed
Year
2026
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-08-20
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li YYishuang
2Zhou ZZhihong
3Lv YYonghui
4Hu HHaoneng
5Chen MMing
6Lei KKunjian
7Gong CChuandong
8Liu JJunzhe
9Yang LLufei
10Huang LLinzhen
11Liu WWenji
12Li JJinying
13Ye MMinhua
14Zhu XXingen
15Huang KKai

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
EndocytosisMajor topic
Receptors, Chimeric AntigenMajor topic
Membrane ProteinsMajor topic
ClathrinMajor topic
Immunotherapy, AdoptiveMajor topic
T-LymphocytesMajor topic
NeoplasmsMajor topic
Animals
Humans
Mice
Cell Line, Tumor
Proteolysis
CTLA-4 Antigen
Xenograft Model Antitumor Assays
Female

Source PubMed

Download CSV of topics

References72

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133824268CAR-T cell therapy: current limitations and potential strategies.Blood Cancer J2021https://conductscience.org/library/papers/33824268PubMed
226369987Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.Leukemia2016https://conductscience.org/library/papers/26369987PubMed
334266984A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.Cancer Discov2021https://conductscience.org/library/papers/34266984PubMed
411994459Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A.J Immunol2002https://conductscience.org/library/papers/11994459PubMed
522262842Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation.J Biol Chem2012https://conductscience.org/library/papers/22262842PubMed
637236024Regulation of protein prenylation.Biomed Pharmacother2023https://conductscience.org/library/papers/37236024PubMed
738307031Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism.Cell Rep Med2024https://conductscience.org/library/papers/38307031PubMed
836108050Robust deep learning-based protein sequence design using ProteinMPNN.Science2022https://conductscience.org/library/papers/36108050PubMed
928622514Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing.Cell2017https://conductscience.org/library/papers/28622514PubMed
1029768164Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells.Immunity2018https://conductscience.org/library/papers/29768164PubMed
11259390634-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.Nat Med2015https://conductscience.org/library/papers/25939063PubMed
1237433327De novo design of protein structure and function with RFdiffusion.Nature2023https://conductscience.org/library/papers/37433327PubMed
1336814099Genetically Programmable Vesicles for Enhancing CAR-T Therapy against Solid Tumors.Adv Mater2023https://conductscience.org/library/papers/36814099PubMed
1431830245Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.Blood2020https://conductscience.org/library/papers/31830245PubMed
1521779028Molecular mechanism and physiological functions of clathrin-mediated endocytosis.Nat Rev Mol Cell Biol2011https://conductscience.org/library/papers/21779028PubMed
1630684591CRISPR-Cas9 for cancer therapy: Opportunities and challenges.Cancer Lett2019https://conductscience.org/library/papers/30684591PubMed
17368356034-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody.Int J Mol Sci2023https://conductscience.org/library/papers/36835603PubMed
1836240777Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells.Cancer Cell2022https://conductscience.org/library/papers/36240777PubMed
1932870222Nucleic acid constructs for the interrogation of multivalent protein interactions.Chem Soc Rev2020https://conductscience.org/library/papers/32870222PubMed
2023671122Transformation of polarized epithelial cells by apical mistrafficking of epiregulin.Proc Natl Acad Sci U S A2013https://conductscience.org/library/papers/23671122PubMed

See all 72 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42514964Mapping Scientific Landscapes and Therapeutic Innovations of Targeted Protein Degradation: A Scientometric Review.Pharmaceutics2026https://conductscience.org/library/papers/42514964PubMed
42140958Identification and functional validation of EPS15L1 as a key driver of triple-negative breast cancer.NPJ Breast Cancer2026https://conductscience.org/library/papers/42140958PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
NR1I39970PubTator's text mininghttps://conductscience.org/library/genes/9970NCBI Gene
TFAP2A7020PubTator's text mininghttps://conductscience.org/library/genes/7020NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41328344

GET https://conductscience.org/api/papers/v1/41328344/references?page=2